Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0PH9I
|
|||
| Drug Name |
AZD5153
|
|||
| Synonyms |
RSMYFSPOTCDHHJ-GOSISDBHSA-N; AZD-5153; 1869912-39-9; UNII-C7C7U6YEAO; C7C7U6YEAO; SCHEMBL17477306; MolPort-044-561-768; AZD 5153 [WHO-DD]; AZD 5153; EX-A1317; BCP20057; ZINC575441177; AKOS030627661; SB18713; AS-35242; J3.544.368A; (3r)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one; XNH; 2-Piperazinone, 4-(2-(4-(1-(3-methoxy-1,2,4-triazolo(4,3-b)pyridazin-6-yl)-4-piperidinyl)phenoxy)ethyl)-1,3-dimethyl-, (3R)-; (R)-4-(2-(4-(1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)pipe
Click to Show/Hide
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
| Company |
AstraZeneca Wilmington, DE
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H33N7O3
|
|||
| Canonical SMILES |
CC1C(=O)N(CCN1CCOC2=CC=C(C=C2)C3CCN(CC3)C4=NN5C(=NN=C5OC)C=C4)C
|
|||
| InChI |
1S/C25H33N7O3/c1-18-24(33)29(2)14-15-30(18)16-17-35-21-6-4-19(5-7-21)20-10-12-31(13-11-20)23-9-8-22-26-27-25(34-3)32(22)28-23/h4-9,18,20H,10-17H2,1-3H3/t18-/m1/s1
|
|||
| InChIKey |
RSMYFSPOTCDHHJ-GOSISDBHSA-N
|
|||
| CAS Number |
CAS 1869912-39-9
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Bromodomain-containing protein 4 (BRD4) | Target Info | Inhibitor | [1] |
| WikiPathways | Chemical Compounds to monitor Proteins | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.